pharmaphorum

JUNE 12, 2025

Skip to main content Thursday 12 June 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

Health and Personal Care Stores 59

Health and Personal Care Stores Diabetes Pharmaceutical Companies Pharmaceutical Companies 59

BioPharma Dive

JULY 9, 2025

Deep Dive Library Events Press Releases Topics Sign up Search Sign up Search Pharma Biotech FDA Clinical Trials Deals Drug Pricing Gene Therapy An article from Dive Brief Actithera draws new investors to radiopharma drug pitch The four-year-old biotech raised about $75 million in a Series A round that involved nine venture capital firms.

Drug Pricing 62

Drug Pricing Compounding Immunization Immunity 62

Putting Patients First Blog

MAY 6, 2025

Food and Drug Administration, Importing Biologics and CBER Regulated Products. 15 Bharath Krishnamurthy and Megha Parikh, Drug Prices and Shortages Jeopardize Patient Access to Quality Hospital Care, AHA News , May 22, 2024, https ://www.aha.org/news/blog/2024-05-22-drug- prices-and-shortages-jeopardize-patient-access-quality-hospital-care.

Pharmaceutical Manufacturing 52

Pharmaceutical Manufacturing Generic Medicine Drug Pricing Hospitals 52

BioPharma Dive

JUNE 26, 2025

Progress developing a treatment for leukemia led the company in 2021 to price a $177 million initial public offering. Daily Dive M-F Commercialization Weekly Every Wednesday Gene Therapy Weekly Every Thursday Emerging Biotech Weekly Every Tuesday By signing up to receive our newsletter, you agree to our Terms of Use and Privacy Policy.

Drug Pricing 43

Drug Pricing Immunization Immunity Drug Development 43

pharmaphorum

JUNE 17, 2025

Skip to main content Tuesday 17 June 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

Diabetes 52

Diabetes Pharmaceutical Companies Pharmaceutical Companies Drug Pricing 52

Pharmaceutical Technology

JUNE 6, 2025

A drug with a recent approval extension in the US, though not the UK, was Supernus Pharmaceuticals’ Qelbree (viloxazine extended-release capsules). Originally approved for children in 2021, the FDA updated the drug’s label in January this year to include adults.

Communication 52

Communication Hospitals Drug Pricing Packaging 52

BioPharma Dive

JULY 2, 2025

Deep Dive Library Events Press Releases Topics Sign up Search Sign up Search Pharma Biotech FDA Clinical Trials Deals Drug Pricing Gene Therapy An article from Dive Brief Organon drug for endometriosis falls short in mid-stage study Company executives had seen the drug as a potential multi-billion dollar opportunity in women’s health.

Drug Pricing 96

Drug Pricing Drug Development Vaccines 96

Pharmaceutical Commerce

JULY 1, 2025

Back in 2021, an estimated 1,582,062 Medicaid recipients were estimated to have at least one out of 379 rare diseases. And in a separate analysis, pediatric patients represent a subgroup in which 40% of them are covered by Medicaid.

Insurance Coverage and Processing 64

Insurance Coverage and Processing Drug Pricing Biosimilars Communication 64

Pharmaceutical Technology

JUNE 10, 2025

By GlobalData Learn more about Strategic Intelligence In April, GlobalData business fundamentals analyst Alison Labya said: “The Trump administration has introduced uncertainty to the biopharmaceutical industry across healthcare policies, drug pricing reforms, and regulatory frameworks, all of which could impact investor confidence.

Drug Pricing 52

Drug Pricing Communication Hospitals Packaging 52

STAT

JANUARY 2, 2025

” It’s the final of three phases in the Centers for Medicare and Medicaid Services’ hospital price transparency rollout. The first phase was the original rollout in 2021, followed by an update in July 2024. Continue to STAT+ to read the full story…

Hospitals 333

Hospitals Drug Pricing 333

BioPharma Dive

JULY 9, 2025

Deep Dive Library Events Press Releases Topics Sign up Search Sign up Search Pharma Biotech FDA Clinical Trials Deals Drug Pricing Gene Therapy An article from Merck to buy Verona and its lung drug in $10B deal The New Jersey-based pharma has inked one of the biggest deals of the year in pursuit of a promising new way to treat COPD.

Drug Pricing 111

Drug Pricing Labelling Pharmaceutical Companies Pharmaceutical Companies 111

STAT

JULY 22, 2024

The findings are likely to intensify scrutiny of the controversial role played by PBMs in the opaque pharmaceutical pricing system. The head of UNAIDS maintained that Gilead could bring the AIDS pandemic toward an end if the company opens up access to its game-changing new HIV drug , Agence France Presse reports.

Drug Pricing 308

Drug Pricing 308

STAT

FEBRUARY 28, 2024

Damian here with a look at a resurgence in psychiatric drug development, a big day for biotech stocks, and some innovation in the world of quarterly earnings. Want to stay on top of the science and politics driving biotech today?    Sign up  to get our biotech newsletter in your inbox. Good morning, everyone.

Drug Development 259

Drug Development Drug Pricing 259

STAT

DECEMBER 6, 2022

During 2021, drugmakers substantially raised prices on seven widely used medicines without any new clinical evidence to justify the increases, leading patients and health insurers in the U.S. to spend an additional $805 million last year, according to a new report.

Drug Pricing 246

Drug Pricing 246

STAT

JANUARY 21, 2023

Compared with a record-busting 2021, private funds to finance growth were harder to come by across the industry last year. And a new federal law to combat high drug prices sent a chill down the industry’s spine. The size and scope of acquisitions were modest. Continue to STAT+ to read the full story…

Drug Pricing 245

Drug Pricing 245

Drug Channels

MAY 10, 2022

When rebates and discounts were factored in, brand-name drug prices declined—or grew slowly—in 2021. Consistent with our previous analyses, rebates and discounts reduced the selling prices of brand-name drugs to less than half of their list prices. healthcare expenditures. healthcare expenditures.

Drug Pricing 98

Drug Pricing Pharmaceutical Manufacturing 98

pharmaphorum

JANUARY 28, 2021

It’s important that the biosimilar market continue to build on the success established last year in 2021. Based on this momentum, we’re making three predictions for 2021: we will see increased competition within individual markets pay off, expansion in the biosimilar channel to include new therapeutic categories, and more regulatory support.

Biosimilars 119

Biosimilars Insurance Coverage and Processing Drug Pricing Diabetes 119

Drug Channels

JULY 28, 2022

When rebates and discounts were factored in, brand-name drug prices declined—or grew slowly—in 2021. Consistent with our previous analyses, rebates and discounts reduced the selling prices of brand-name drugs to less than half of their list prices. healthcare expenditures. healthcare expenditures.

Drug Pricing 98

Drug Pricing Pharmaceutical Manufacturing 98

STAT

JULY 22, 2024

The findings are likely to intensify scrutiny of the controversial role played by PBMs in the opaque pharmaceutical pricing system. Notably, nearly half of the overcharges stemmed from drug rebates that Express Scripts negotiated with pharmaceutical companies.

Pharmaceutical Companies 364

Pharmaceutical Companies Pharmaceutical Companies Drug Pricing 364

Drug Channels

SEPTEMBER 13, 2021

Informa Connect’s Drug Pricing Transparency Congress. Delivered as a Hybrid Event In-Person: November 9-10 | Philadelphia, PA Virtual: November 16-17 www.informaconnect.com/drug-pricing-transparency. Drug Channels, or any of its employees. Copyright © 2006-2021 Pembroke Consulting, Inc.

Drug Pricing 75

Drug Pricing 75

Drug Channels

SEPTEMBER 28, 2021

Curl up with your favorite pumpkin-spiced blog and savor these stories harvested from the Drug Channels patch: Fresh insights about hospitals’ specialty drug profits SSR Update: Drug prices keep dropping My $0.02 Read more » Copyright © 2006-2021 Pembroke Consulting, Inc. d/b/a Drug Channels Institute.

Drug Pricing 81

Drug Pricing Hospitals Biosimilars 81

Drug Channels

SEPTEMBER 24, 2023

Drug Channels has just obtained new details on the size of the 340B Drug Pricing Program. billion (+22.3%) higher than its 2021 counterpart. The difference between list prices and discounted 340B purchases also grew, to $52.3 The difference between list prices and discounted 340B purchases also grew, to $52.3

Drug Pricing 96

Drug Pricing Hospitals 96

Drug Channels

MARCH 8, 2022

It’s the 13th edition of our popular and comprehensive examination of the entire drug pricing, reimbursement, and dispensing system. prescription dispensing revenues for calendar year 2021. prescription dispensing revenues reached a record $501 billion in 2021.

Drug Pricing 98

Drug Pricing 98

STAT

MAY 6, 2024

A battle between the Arkansas Insurance Department and AstraZeneca is heating up with an August hearing scheduled to consider penalties against the company, which filed a lawsuit against the state earlier this year over a law known as the 340B Drug Pricing Nondiscrimination Act, The Arkansas Democrat-Gazette reports.

Drug Pricing 265

Drug Pricing 265

Drug Channels

AUGUST 15, 2022

Here’s a summer surprise for fans of the 340B Drug Pricing Program: Drug Channels has just obtained the 2021 figures from the Health Resources and Services Administration (HRSA)! For 2021, discounted purchases under the 340B program reached a record $43.9 The data tell a familiar story. billion —an astonishing $5.9

Hospitals 98

Hospitals Drug Pricing 98

Drug Channels

DECEMBER 15, 2023

Drug Channels has just obtained new details on the size of the 340B Drug Pricing Program. billion (+22.3%) higher than its 2021 counterpart. The difference between list prices and discounted 340B purchases also grew, to $52.3 The difference between list prices and discounted 340B purchases also grew, to $52.3

Drug Pricing 98

Drug Pricing Hospitals 98

STAT

JULY 24, 2023

AbbVie, Teva Pharmaceutical, and AstraZeneca left over a span of five months following the passage of the drug-pricing reform law pushed by Democrats last year. Drug companies are systematically funding grassroots patient groups that lobby the U.K. Financial interests were often not clearly disclosed in NICE documents.

Drug Pricing 244

Drug Pricing Documentation 244

Drug Channels

JULY 26, 2022

This week, I’m rerunning some popular posts while I prepare for this Friday’s live video webinar: Specialty Drugs Update: Trends, Controversies, and Outlook. More than $122 billion in "savings" (offsets) from the current drug pricing reconciliation legislation comes from blocking rebate reform—which never even happened.

Drug Pricing 94

Drug Pricing 94

STAT

APRIL 10, 2024

From 2012 to 2021, Regeneron’s credit card fee reimbursements for Eylea purchases exceeded $250 million to just one of its several distributors. Continue to STAT+ to read the full story…

Drug Pricing 324

Drug Pricing 324

Drug Channels

DECEMBER 16, 2022

Fortunately, my 2022 FOIA efforts (described below) extracted purchases by 340B covered entity type for 2015 through 2021. Here’s a summer surprise for fans of the 340B Drug Pricing Program: Drug Channels has just obtained the 2021 figures from the Health Resources and Services Administration (HRSA)!

Hospitals 97

Hospitals Drug Pricing 97

STAT

MARCH 20, 2024

At the time, traveling abroad for the therapy, which is manufactured by Orchard Therapeutics and was approved in Europe in 2021, was the only option for families stricken by MLD. But soon it will be available in the U.S., Continue to STAT+ to read the full story…

Drug Pricing 363

Drug Pricing 363

Drug Channels

DECEMBER 8, 2020

When Americans complains about “drug prices,” most are actually complaining about the share of costs they pay—and how those costs are computed. drug channel. Today, I review four crucial issues that the new Congress could tackle to address affordability, patients' out-of-pocket obligations, and prescription prices.

Drug Pricing 52

Drug Pricing 52

Drug Channels

MARCH 25, 2021

This week, I’m rerunning some popular posts while I prepare for tomorrow's live video webinar: Drug Channels Quarterly Update: Patients, Payers, and PBMs. When Americans complain about “drug prices,” most are actually complaining about the share of costs they pay—and how those costs are computed. drug channel.

Drug Pricing 52

Drug Pricing 52

STAT

MAY 4, 2023

Between 2012 and 2021, 14% of roughly 19,000 patent applications did not disclose financial support from the NIH or did not do so as required by federal law. And a new analysis finds a key reason may be most institutions and researchers that receive NIH support fail to fully or correctly disclose this information when applying for patents.

Drug Development 259

Drug Development Drug Pricing 259

STAT

OCTOBER 18, 2023

… Investors in biopharma companies, who lobbied vigorously — but unsuccessfully — against allowing Medicare to negotiate drug prices, are trying a new tactic to preserve their profits , The Boston Globe tells us.  Between 2017 and 2021, annual new HIV infections fell by 12%.

Drug Pricing 272

Drug Pricing 272

STAT

DECEMBER 29, 2022

The downfall of Aduhelm, the first new treatment for Alzheimer’s disease in two decades, is largely the story of a drug company choosing to maximize its potential profits at the expense of patients and taxpayers, according to a congressional investigation that cites thousands of pages of internal Biogen documents.

Documentation 246

Documentation Drug Pricing 246

Drug Channels

MARCH 21, 2022

Time for Drug Channels Institute’s annual update on the gross-to-net bubble —the ever-growing dollar gap between sales at brand-name drugs' list prices and their sales at net prices after rebates and other reductions. drug prices. d/b/a Drug Channels Institute.

Drug Pricing 75

Drug Pricing 75